Charles River Laboratories International, Inc.
CRL
$155.46
$2.801.83%
NYSE
| 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | |
|---|---|---|---|---|---|
| Revenue | 994.23M | 1.00B | 1.03B | 984.17M | 1.00B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 994.23M | 1.00B | 1.03B | 984.17M | 1.00B |
| Cost of Revenue | 665.36M | 652.72M | 648.60M | 644.07M | 682.87M |
| Gross Profit | 328.87M | 352.13M | 383.54M | 340.10M | 319.68M |
| SG&A Expenses | 192.02M | 173.65M | 185.82M | 176.32M | 193.23M |
| Depreciation & Amortization | 92.01M | 27.40M | 25.68M | 29.76M | 41.22M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 949.40M | 853.77M | 860.10M | 850.15M | 917.33M |
| Operating Income | 44.83M | 151.08M | 172.03M | 134.01M | 85.22M |
| Income Before Tax | -294.10M | 87.20M | 71.42M | 35.98M | -216.79M |
| Income Tax Expenses | -17.81M | 31.64M | 18.73M | 10.10M | -3.04M |
| Earnings from Continuing Operations | -276.29M | 55.56M | 52.69M | 25.88M | -213.75M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -265.00K | -1.13M | -367.00K | -409.00K | -748.00K |
| Net Income | -276.56M | 54.42M | 52.33M | 25.47M | -214.50M |
| EBIT | 44.83M | 151.08M | 172.03M | 134.01M | 85.22M |
| EBITDA | 169.61M | 165.25M | 327.04M | 218.88M | 150.23M |
| EPS Basic | -5.62 | 1.11 | 1.06 | 0.50 | -4.22 |
| Normalized Basic EPS | 0.44 | 1.30 | 1.82 | 1.17 | 0.50 |
| EPS Diluted | -5.62 | 1.10 | 1.06 | 0.50 | -4.22 |
| Normalized Diluted EPS | 0.44 | 1.30 | 1.81 | 1.16 | 0.50 |
| Average Basic Shares Outstanding | 49.22M | 49.21M | 49.15M | 50.68M | 51.14M |
| Average Diluted Shares Outstanding | 49.22M | 49.43M | 49.32M | 50.85M | 51.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |